<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Ipamorelin</title>
          <meta name="description" content="Curated source summaries for Ipamorelin." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Ipamorelin</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Ipamorelin" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Ipamorelin</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 See also</li><li>2 References</li><li>3 External links</li><li># Ipamorelin</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikidata item</li><li>None</li><li>(2 S )-6-Amino-2-[[(2 R )-2-[[(2 R )-2-[[(2 S )-2-[(2-amino-2-methylpropanoyl)amino]-3-(4 H -imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide.</li><li>170851-70-4</li><li>20754357</li><li>8007390</li><li>Y9M3S784Z6</li><li>DTXSID80168955</li><li>Interactive image</li><li>CC(C)(C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N</li><li>InChI=1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1</li><li>Key:NEHWBYHLYZGBNO-BVEPWEIPSA-N</li><li>Ipamorelin ( INN ; development code NNC 26-0161 ) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue . [ 2 ] [ 3 ] It is a pentapeptide with the amino acid sequence Aib-His- D -2-Nal- D -Phe-Lys-NH 2 that was derived from GHRP-1 . [ 4 ]</li><li>Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans. [ 1 ] [ 3 ] [ 5 ] In addition, ipamorelin stimulates body weight gain in animals. [ 5 ] Like pralmorelin and GHRP -6, ipamorelin does not affect prolactin , follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels. [ 3 ] However, unlike pralmorelin (GHRP-2) and GHRP-6 , but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH), or cortisol , and is highly selective for inducing the secretion only of GH. [ 3 ]</li><li>Ipamorelin was originally developed by Novo Nordisk , and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus , but was discontinued due to lack of efficacy. [ 6 ] [ 7 ]</li><li>Ipamorelin has been used by athletes as a performance enhancing drug . [ 8 ] [ 9 ] [ 10 ] Currently, Ipamorelin is commonly marketed as a research peptide rather than as an approved pharmaceutical drug. [ 11 ]</li><li># See also</li><li>List of growth hormone secretagogues</li><li># References</li><li>^ a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} Gobburu JV, Agersø H, Jusko WJ, Ynddal L (September 1999). "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers". Pharmaceutical Research . 16 (9): 1412– 6. doi : 10.1023/A:1018955126402 . PMID 10496658 . S2CID 12048934 .</li><li>^ Moulin A, Ryan J, Martinez J, Fehrentz JA (September 2007). "Recent developments in ghrelin receptor ligands". ChemMedChem . 2 (9): 1242– 59. doi : 10.1002/cmdc.200700015 . PMID 17520591 . S2CID 24945528 .</li><li>^ a b c d Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (November 1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology . 139 (5): 552– 61. doi : 10.1530/eje.0.1390552 . PMID 9849822 .</li><li>^ Isidro ML, Cordido F (March 2006). "Growth hormone secretagogues". Combinatorial Chemistry & High Throughput Screening . 9 (3): 175– 80. doi : 10.2174/138620706776055458 . PMID 16533150 .</li><li>^ a b Jiménez-Reina L, Cañete R, De la Torre MJ, Bernal G (2002). "Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats" . European Journal of Anatomy . 6 (1): 37– 46. ISSN 1136-4890 .</li><li>^ Beck DE, Sweeney WB, McCarter MD (December 2014). "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients". International Journal of Colorectal Disease . 29 (12): 1527– 34. doi : 10.1007/s00384-014-2030-8 . PMID 25331030 . S2CID 22869695 .</li><li>^ "Ipamorelin" . AdisInsight . Springer Nature Switzerland AG . Retrieved 10 June 2015 .</li><li>^ Perez AJ (5 May 2016). "Peptides under greater scrutiny in MLB's performance-enhancing drug battle" . USA TODAY . Retrieved 2018-04-14 .</li><li>^ Maloney J (13 April 2018). "NBA Playoffs 2018: Wizards' Jodie Meeks suspended 25 games for failing drug test" . CBSSports.com . Retrieved 2018-04-14 .</li><li>^ "Nets' Chandler suspended 25 games for PED use" . nba.com . Retrieved 2019-08-30 .</li><li>^ "Ipamorelin" . PurePep . Retrieved 2026-01-05 .</li><li># External links</li><li>v</li><li>t</li><li>e</li><li>Agonists: Albusomatropin</li><li>Bovine somatotropin</li><li>Efpegsomatropin</li><li>Eftansomatropin alfa</li><li>Growth hormone</li><li>Human placental lactogen</li><li>Lonapegsomatropin</li><li>Placental growth hormone (growth hormone variant)</li><li>Somagrebove</li><li>Somapacitan</li><li>Somatosalm</li><li>Somatotropin</li><li>Somatropin pegol</li><li>Somatrem</li><li>Sometribove</li><li>Somatrogon (MOD-4023; hGH-CTP)</li><li>Somavaratan</li><li>Somavubove</li><li>Somidobove</li><li>Antagonists: G120K-hGH</li><li>Pegvisomant</li><li>Antisense oligonucleotides: Atesidorsen</li><li>Binding proteins: GHBP Tooltip Growth hormone-binding protein</li><li>Agonists: BIM-23052</li><li>CH-275</li><li>Cortistatin-14</li><li>Depreotide</li><li>Edotreotide</li><li>Ilatreotide</li><li>L-803,087</li><li>L-817,818</li><li>Lanreotide</li><li>NNC 26-9100</li><li>Octreotate</li><li>Octreotide</li><li>Pasireotide</li><li>Pentetreotide</li><li>RC-160</li><li>Seglitide</li><li>Somatostatin (GHIH)</li><li>Somatostatin (1-28)</li><li>SRIF-14</li><li>SRIF-28</li><li>TT-232</li><li>Vapreotide</li><li>Veldoreotide</li><li>Antagonists: BIM-23056</li><li>Cyclosomatostatin</li><li>CYN-154806</li><li>Satoreotide</li><li>Agonists: Peptide: ALRN-5281</li><li>CJC-1295</li><li>Dumorelin</li><li>GHRH</li><li>Modified GRF (1-29)</li><li>Rismorelin</li><li>Sermorelin</li><li>Somatorelin</li><li>Tesamorelin</li><li>Antagonists: MZ-5-156</li><li>Agonists: Peptide: Alexamorelin</li><li>EP-51216</li><li>Examorelin (hexarelin)</li><li>Ghrelin</li><li>GHRP-1</li><li>GHRP-3</li><li>GHRP-4</li><li>GHRP-5</li><li>GHRP-6</li><li>Ipamorelin</li><li>Lenomorelin</li><li>Livoletide</li><li>LY-444711</li><li>Pralmorelin (GHRP-2)</li><li>Relamorelin</li><li>Tabimorelin</li><li>Ulimorelin ; Non-peptide: Adenosine</li><li>Anamorelin</li><li>Capromorelin</li><li>CP-464709</li><li>Ibutamoren (MK-677)</li><li>L-692,585</li><li>Macimorelin</li><li>SM-130686 ; Unsorted: LY-426410</li><li>Antagonists: A-778193</li><li>Cortistatin-8</li><li>( D -Lys³)-GHRP-6</li><li>JMV2959</li><li>YIL-781</li><li>See here instead.</li><li>Drugs not assigned an ATC code</li><li>Abandoned drugs</li><li>Ghrelin receptor agonists</li><li>Growth hormone secretagogues</li><li>Imidazoles</li><li>2-Naphthyl compounds</li><li>Peptide therapeutics</li><li>World Anti-Doping Agency prohibited substances</li><li>Articles with short description</li><li>Short description is different from Wikidata</li><li>Articles without EBI source</li><li>Chemical pages without DrugBank identifier</li><li>Articles without KEGG source</li><li>Drugs with no legal status</li><li>Articles containing unverified chemical infoboxes</li><li>This page was last edited on 5 January 2026, at 05:49 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubmed.ncbi.nlm.nih.gov/11206045/" rel="noopener noreferrer" target="_blank">https://pubmed.ncbi.nlm.nih.gov/11206045/</a></p>
  <ul>
    <li># Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography</li><li># Authors</li><li># Affiliation</li><li>1 Department of Pharmacotoxicology, Avicenne University Hospital, Bobigny, France.</li><li>PMID: 11206045</li><li>DOI: 10.1097/00007691-200102000-00011</li><li># Abstract</li><li>A rapid, sensitive, and specific liquid chromatography method for the simultaneous determination of four protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir) in human plasma is described. After a liquid-liquid extraction with terbutyl methyl ether and a sequential washing of the reconstituted sample with hexane, protease inhibitors are separated on a phenyl column using a simple binary mobile phase of ammonium acetate buffer:acetonitrile (48:52) (pH = 7.5) with an ultraviolet detection at 260 nm. The standard curves are linear in the range 0.025-1 microg/mL for saquinavir, 0.1-4 microg/mL for indinavir and nelfinavir, and 0.25-10 microg/mL for ritonavir, with an average recovery ranging from 79% to 99%, and with both low interday and intraday coefficients of variation (<15%). This assay is simple, rapid (15-minute interval between runs) , and useful for therapeutic monitoring of the protease inhibitors on a routine basis.</li><li># MeSH terms</li><li>Calibration</li><li>Chromatography, High Pressure Liquid</li><li>Drug Monitoring</li><li>HIV Protease Inhibitors / blood*</li><li>Humans</li><li>Indicators and Reagents</li><li>Indinavir / blood</li><li>Nelfinavir / blood</li><li>Reference Standards</li><li>Ritonavir / blood</li><li>Saquinavir / blood</li><li>Spectrophotometry, Ultraviolet</li><li># Substances</li><li>HIV Protease Inhibitors</li><li>Indinavir</li><li>Nelfinavir</li><li>Saquinavir</li><li>Ritonavir</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
